Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin

Scandinavian Journal of Infectious Diseases

Volumn 40, Issue 2, 2008, Pages 94-104

  Hijnen, Marcel ^a,b   He, Qiushui ^c   Schepp, Rutger ^a   Van Gageldonk, Pieter ^a   Mertsola, Jussi ^d   Mooi, Frits R ^a,b   Berbers, Guy A M ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; EPITOPE; VIRULENCE FACTOR;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BORDETELLA PERTUSSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; NONHUMAN; PERTUSSIS; PROTEIN DEPLETION; PROTEIN LOCALIZATION;

ANIMALS; ANTIBODY SPECIFICITY; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PARAPERTUSSIS; BORDETELLA PERTUSSIS; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; RABBITS; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 38149064554     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.1080/00365540701642138     Document Type: Article

References (28)

1. Kerr, JR and Matthews, RC. (2000) Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity. Eur J Clin Microbiol Infect Dis, 19, pp. 77-88.
2. Mooi, FR, van Loo, IH and King, AJ. (2001) Adaptation of Bordetella pertussis to vaccination: A cause for its re-emergence?. Emerg Infect Dis, 7, pp. 526-528.
3. Bass, JW and Wittler, RR. (1994) Return of epidemic pertussis in the United States. Pediatr Infect Dis J, 13, pp. 343-345.
4. de Melker, HE, Spaendonck, MA Conyn-van, Rumke, HC, van Wijngaarden, JK, Mooi, FR and Schellekens, JF. (1997) Pertussis in the Netherlands: An outbreak despite high levels of immunization with whole cell vaccine. Emerg Infect Dis, 3, pp. 175-178.
5. de Melker, HE, Schellekens, JF, Neppelenbroek, SE, Mooi, FR, Rumke, HC and Spaendonck, MA. Conyn-van (2000) Re-emergence of pertussis in the highly vaccinated population of the Netherlands: Observations on surveillance data. Emerg Infect Dis, 6, pp. 348-357.
6. Lin, YC, Yao, SM, Yan, JJ, Chen, YY, Chiang, CS and Wu, HS (2007) Epidemiological shift in the prevalence of pertussis in Taiwan: implications for pertussis vaccination. J Med Microbiol, 56, pp. 533-537.
7. Mastrantonio, P., Spigaglia, P., van Oirschot, H., van der Heide, HG, Heuvelman, K. and Stefanelli, P. (1999) Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology, 145, pp. 2069-2075.
8. Mooi, FR, He, Q., van Oirschot, H. and Mertsola, J. (1999) Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun, 67, pp. 3133-3134.
9. Fry, NK, Neal, S., Harrison, TG, Miller, E., Matthews, R. and George, RC. (2001) Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun, 69, pp. 5520-5528.
10. Cassiday, P., Sanden, G., Heuvelman, K., Mooi, F., Bisgard, KM and Popovic, T. (2000) Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis, 182, pp. 1402-1408.
11. Gzyl, A., Augustynowicz, E., Loo, I. and Slusarczyk, J. (2001) Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland. Vaccine, 20, pp. 299-303.
12. Gzyl, A., Augustynowicz, E., Gniadek, G., Rabczenko, D., Dulny, G. and Slusarczyk, J. (2004) Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: Efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates. Vaccine, 22, pp. 2122-2128.
13. Guiso, N., Boursaux-Eude, C., Weber, C., Hausman, SZ, Sato, H. and Iwaki, M. (2001) Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine, 19, pp. 3248-3252.
14. Kourova, N., Caro, V., Weber, C., Thiberge, S., Chuprinina, R. and Tseneva, G. (2003) Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains. J Clin Microbiol, 41, pp. 3706-3711.
15. Andrews, R., Herceg, A. and Roberts, C. (1997) Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell, 21, pp. 145-148.
16. Poynten, M., McIntyre, PB, Mooi, FR, Heuvelman, KJ and Gilbert, GL. (2004) Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol Infect, 132, pp. 185-193.
17. Gustafsson, L., Hessel, L., Storsaeter, J. and Olin, P. (2006) Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 y of age. Pediatrics, 118, pp. 978-984.
18. Caro, V., Bouchez, V., Guiso, N., Gatti, B., Agosti, MR and Ayala, SE (2006) Pertussis in Argentina and France. Vaccine
19. Halperin, SA. (2007) The control of pertussis-2007 and beyond. N Engl J Med, 356, pp. 110-113.
20. Cherry, JD, Gornbein, J., Heininger, U. and Stehr, K. (1998) A search for serological correlates of immunity to Bordetella pertussis cough illnesses. Vaccine, 16, pp. 1901-1906.
21. Storsaeter, J., Hallander, HO, Gustafsson, L. and Olin, P. (1998) Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine, 16, pp. 1907-1916.
22. He, Q., Makinen, J., Berbers, G., Mooi, FR, Viljanen, MK and Arvilommi, H. (2003) Bordetella pertussis protein pertactin induces type-specific antibodies: One possible explanation for the emergence of antigenic variants?. J Infect Dis, 187, pp. 1200-1205.
23. Hijnen, M. (2006) The Bordetella pertussis protein pertactin: Role in immunity and immune evasion.
24. Hijnen, M., van Gageldonk, PG, Berbers, GA, van Woerkom, T. and Mooi, FR. (2005) The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif, 41, pp. 106-112.
25. Junker, M., Schuster, CC, McDonnell, AV, Sorg, KA, Finn, MC and Berger, B. (2006) Pertactin beta-helix folding mechanism suggests common themes for the secretion and folding of autotransporter proteins. Proc Natl Acad Sci U S A, 103, pp. 4918-4923.
26. Mooi, FR, van Oirschot, H., Heuvelman, K., van der Heide, HG, Gaastra, W. and Willems, RJ. (1998) Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun, 66, pp. 670-675.
27. Hijnen, M., Mooi, FR, van Gageldonk, PG, Hoogerhout, P., King, AJ and Berbers, GA. (2004) Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun, 72, pp. 3716-3723.
28. Carson, M., Johnson, DH, McDonald, H., Brouillette, C. and Delucas, LJ. (2007) His-tag impact on structure. Acta Crystallogr D Biol Crystallogr, 63, pp. 295-301.